Clinical significance of rapid detecting bone marrow BCL2/IGH and BCL6/IGH fusion genes in patients with diffuse large B cell lymphoma by multiplex PCR.
- Author:
Yue-Lu GUO
1
;
Li-Li DONG
;
Li GAO
;
Yuan-Yuan XU
;
Yi DING
;
Li-Li WANG
;
Yu JING
;
Jian BO
;
Min-Hang ZHOU
;
Ting-Ting CAO
;
Li YU
Author Information
1. Department of Hematology, Chinese PLA General Hospital, Beijing 100853, China.
- Publication Type:Journal Article
- MeSH:
Adult;
Aged;
Aged, 80 and over;
Bone Marrow;
pathology;
Female;
Humans;
Immunoglobulin Heavy Chains;
genetics;
Lymphoma, Large B-Cell, Diffuse;
genetics;
pathology;
Male;
Middle Aged;
Multiplex Polymerase Chain Reaction;
Oncogene Proteins, Fusion;
genetics;
Proto-Oncogene Proteins c-bcl-2;
genetics;
Proto-Oncogene Proteins c-bcl-6;
genetics;
Young Adult
- From:
Journal of Experimental Hematology
2012;20(6):1370-1373
- CountryChina
- Language:Chinese
-
Abstract:
Diffuse large B cell lymphoma (DLBCL) is the most common aggressive non-Hodgkin's lymphoma (NHL), characterized by great heterogeneity in clinical manifestations and molecular genetics. This study was aimed to explore the clinical significance of applying multiplex PCR to detect BCL2/IGH and BCL6/IGH fusion genes in DLBCL. Multiplex PCR was used to detect bone marrow samples from 80 cases of DLBCL. The results showed that 12 patients (15%) carried BCL2/IGH or BCL6/IGH fusion genes, BCL2/IGH was found in 6 patients (7.5%), and BCL6/IGH in another 6 patients (7.5%). The patients with different molecular markers displayed different clinical features and outcomes. It is concluded that multiple PCR is rapid and accurate method to identify gene abnormalities in DLBCL, but further studying a quantitative or semi-quantitative assay for the expression of fusion genes is needed.
